Member Info for rafidel

Key Forecasts and Projections:

Bullish Case (Clear Capital Markets): A "Strong Buy" recommendation suggests a 12-month target of 30p, representing a potential +1100% upside from 2.5p, driven by an "Amazon-style" scaling of healthcare.

MedPal AI (MPAL) shares, trading around 2.5p–2.7p as of early May 2026, face a wide range of forecasts, with some analysts noting a 12-month target of 30p based on aggressive growth projections. The company, which operates AI-driven healthcare services, has reported rapid growth, over £1.5M in recent revenue, and ambitious expansion plans aimed at high-value clinic segments.

Looking Very Strong Going Forward.. Path to Pharmacy Breakeven

The Group now operates two GPhC-registered NHS dispensing hubs (Swaffham and Runcorn) under a common technology, clinical governance and commercial infrastructure. At their peak in 2024, Runcorn dispensed over 100,000 items per month and the facility in Swaffham dispensed over 30,000 items per month. Management forecasts pharmacy-level EBITDA breakeven for the Group at a run rate of 80,000 items per month and in March dispensed over 40,000. NHS pharmacy gross margins are in excess of 34%, with strong operating leverage as fixed costs are absorbed over rising volumes. This is a pharmacy operating-company metric; Group profitability additionally benefits from continued growth at MedPal.clinic, MedPal Health OS and the at-home blood test kit business, each of which complements all of the other elements of the MedPal Group via customer introduction and data sharing to provide customers with personalised, real-time healthcare.

Fair Value end of year 8p or higher